T2 Biosystems, Inc. (NASDAQ:TTOO – Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 826,900 shares, a decrease of 12.3% from the December 31st total of 942,500 shares. Approximately 6.6% of the shares of the company are sold short. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is presently 0.8 days.
T2 Biosystems Stock Up 2.4 %
NASDAQ TTOO opened at $0.22 on Monday. The stock’s 50-day moving average price is $0.38 and its 200-day moving average price is $1.75. T2 Biosystems has a 52 week low of $0.21 and a 52 week high of $6.95.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of T2 Biosystems in a report on Wednesday, January 29th. They issued a “sell” rating on the stock.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Read More
- Five stocks we like better than T2 Biosystems
- What Are Earnings Reports?
- 3 REITs to Watch as Interest Rates Keep Falling
- What is a Death Cross in Stocks?
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
